Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | QuANTUM-First: association between FLT3-ITD-specific MRD clearance and survival in patients with AML

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, highlights findings from the Phase III QuANTUM-First trial (NCT02668653), which investigated the efficacy of the selective FLT3 inhibitor quizartinib in patients with acute myeloid leukemia (AML). Dr Perl explains that this study demonstrated that treatment with intensive induction chemotherapy and quizartinib improved overall survival for patients with newly diagnosed FLT3-ITD+ AML. In addition to this, a reduction in the FLT3-ITD-specific measurable residual disease (MRD) burden was associated with improved survival in all treatment arms. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Astellas, Daiichi Sankyo, AbbVie, Forma, Sumitomo Dainippon, BeatAML LLC: Consultancy; Astellas, Abbvie, Daiichi Sankyo, FujiFilm, Syndax: Research Funding; Astellas, Daiichi Sankyo, Abbvie, Genentech, BerGenBio, Immunogen, BMS/Celgene, Actinium: Membership on an entity’s Board of Directors or advisory committees.